Login / Signup

[The experience in treatment of dengue fever using antiviral drug riamilovir in the Republic of Guinea (case report)].

O V MaltsevK V KasyanenkoK V ZhdanovN A MalyshevE V KolomoetsV K Konomou
Published in: Terapevticheskii arkhiv (2023)
Dengue fever is classified as one of the most common viral diseases with a transmission mechanism implemented through arthropod vectors. The expansion of of the Aedes aegypti mosquito is leading to a significant increase in the number of cases of dengue fever in more than 100 countries, highlighting the importance of developing and implementing specific prevention and treatment measures. Etiotropic drugs with proven efficacy against the pathogen are not registered, and the use of the vaccine is approved only among seropositive individuals. In this regard, pathogenetic treatment remains the main therapeutic strategy, however, work on the synthesis of antiviral drugs is being actively carried out. Due to the unique functions of non-structural proteins NS3 and NS5 in the viral replication cycle, they have become the main targets for studying the antiviral activity of a number of chemotherapy drugs. Of these proteins, due to the most conserved structure, the NS5 protein is a promising target for inhibition, however, success in obtaining a clinical effect using a number of available antiviral drugs has not been reached. This study describes the positive experience of using the nucleoside analogue riamilovir in the treatment of a patient with dengue fever in the Republic of Guinea.
Keyphrases
  • aedes aegypti
  • dengue virus
  • zika virus
  • case report
  • emergency department
  • sars cov
  • small molecule
  • squamous cell carcinoma
  • protein protein
  • adverse drug